Here's what we'll cover
Here's what we'll cover
Medicare's $50 GLP-1 Bridge: A Real Step With a Frustrating Asterisk
If you're on Medicare and have been waiting for help paying for a GLP-1, there is real news. Since July 1, 2026, the Medicare GLP-1 Bridge has let eligible Part D enrollees get certain GLP-1 weight loss medications for $50 a month. But the program has rules that leave out some of the people who might need these drugs most, including many who are already managing serious health conditions.
Understanding exactly where the lines are drawn matters when the alternative can be several hundred to more than $1,000 a month.
What the Medicare GLP-1 Bridge Covers
The Bridge is a temporary demonstration run by the Centers for Medicare and Medicaid Services (CMS). It runs from July 1, 2026, through December 31, 2027, and it operates outside your regular Part D plan. Eligible enrollees pay $50 for a one month supply of one of these drugs:
- Foundayo (orforglipron) tablets from Eli Lilly
- Wegovy (semaglutide) as an injection or a tablet
- Zepbound (tirzepatide) KwikPen only. Single dose Zepbound vials and pens are not covered.
Before the Bridge, Part D could only pay for these drugs for other approved uses, such as type 2 diabetes or reducing cardiovascular risk. Weight management on its own was excluded by law.
Who Qualifies for the $50 Price
According to Medicare, you must meet all of these requirements:
- You have Part D drug coverage through a standalone drug plan or a Medicare Advantage plan that includes drug coverage. Some special plan types, such as private fee for service plans, cost plans, and PACE, are not eligible.
- You are 18 or older and are using the GLP-1 for weight management.
- You do not have type 2 diabetes, moderate to severe obstructive sleep apnea, or fatty liver disease (MASH).
- You meet the BMI criteria, measured at the time you started GLP-1 therapy.
The BMI criteria fall into three tiers:
- BMI of 35 or higher, with no other condition required.
- BMI of 30 or higher plus heart failure with preserved ejection fraction or uncontrolled high blood pressure. CMS prescriber guidance also lists chronic kidney disease stage 3a or higher.
- BMI of 27 or higher plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Who Gets Left Out
This is the catch. Several groups can't use the Bridge even if they meet the BMI rules.
People With Type 2 Diabetes, Sleep Apnea, or Fatty Liver Disease
If you have type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH, you are excluded from the Bridge. CMS's reasoning is that these are approved Part D uses, so your regular drug plan is supposed to cover your GLP-1. In practice, that means you pay whatever your plan charges, which depends on its formulary, tier, deductible, and prior authorization rules, and it can be more than $50 a month.
This is the painful irony of the program. The patients with the most advanced metabolic disease are routed to coverage that may cost them more than the flat $50 rate available to people with fewer diagnoses.
People Already Getting a GLP-1 Through Part D
If your Part D plan has paid for a GLP-1, you aren't eligible for the Bridge right now. You can keep getting your medication through your plan. CMS also says people being treated to reduce the risk of major cardiovascular events, which is an approved Part D use for Wegovy, should continue seeking coverage through Part D.
People Below the BMI Thresholds or on Other Drugs
If your starting BMI and conditions don't match one of the three tiers, the Bridge won't cover you. It also does not cover Ozempic, Mounjaro, compounded GLP-1s, or Zepbound vials.
Everyone, Eventually
The Bridge is scheduled to end on December 31, 2027. What happens after that depends on future CMS policy or legislation, so it is not a permanent solution.
How the $50 Price Interacts With Part D Costs
The $50 Bridge copay does not count toward your Part D deductible or your yearly out of pocket cap. That cap is set at $2,000 in 2025 and $2,100 in 2026. The old Part D coverage gap, often called the donut hole, no longer exists.
If your GLP-1 is covered through Part D instead, for example for type 2 diabetes, your costs do count toward the cap. Once you reach it, you pay nothing more for covered drugs that year. The Medicare Prescription Payment Plan lets you spread those costs into monthly payments, but you have to ask your plan to enroll you.
What the Cost Looks Like by Route
| Route | Who It Applies To | Approximate Monthly Cost |
|---|---|---|
| Medicare GLP-1 Bridge | Eligible Part D enrollees using Foundayo, Wegovy, or Zepbound KwikPen for weight management | $50 |
| Regular Part D coverage | Enrollees with type 2 diabetes, sleep apnea, MASH, or cardiovascular risk reduction | Depends on your plan; counts toward the $2,100 cap in 2026 |
| List price | Anyone paying full retail without a program | About $1,086 to $1,349 depending on the drug |
| Manufacturer savings cards | Commercially insured patients only | Not available to Medicare beneficiaries |
| Manufacturer patient assistance programs | Patients who meet income limits, including some Medicare beneficiaries | Free or reduced cost for those who qualify |
What You Can Do If You Don't Qualify
Not qualifying for the Bridge is frustrating, but it doesn't mean you're out of options.
Use Your Part D Coverage for Covered Conditions
If you were excluded because you have type 2 diabetes, sleep apnea, or MASH, ask your doctor to prescribe through your Part D plan for that condition. Check your plan's formulary, start any prior authorization early, and ask whether a different GLP-1 sits on a lower cost tier.
Request a Formulary Exception
If your plan doesn't cover the GLP-1 your doctor recommends, you or your doctor can ask for a formulary exception. Your doctor will need to write a letter of medical necessity explaining why a lower cost alternative won't work for you. It's not guaranteed, but it succeeds often enough to be worth trying.
Apply for Extra Help
If your income and savings are limited, Medicare's Extra Help program can lower Part D premiums and copays. It does not change the Bridge price, which is $50 for everyone who qualifies, but it can make Part D covered GLP-1s more affordable.
Explore Patient Assistance Programs
Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Mounjaro, Zepbound, and Foundayo) run patient assistance programs for people who meet income criteria, including some Medicare beneficiaries. These are separate from commercial savings cards, which Medicare beneficiaries can't use.
You can also compare options on our Best Providers page and check the GLP-1 Coupons page for current programs, keeping in mind that many discounts exclude Medicare.
Questions to Ask Your Doctor Before Your Next Appointment
If you're a Medicare beneficiary trying to navigate GLP-1 access, these questions can help you use your appointment time effectively.
- Based on my BMI when I started and my diagnoses, do I meet the Medicare GLP-1 Bridge criteria?
- If I have type 2 diabetes, sleep apnea, or MASH, which GLP-1 does my Part D plan cover, and what will I pay?
- Can you submit the Bridge prior authorization or a Part D prior authorization for me?
- If my plan denies coverage, will you write a letter of medical necessity for a formulary exception?
- What is our plan for my treatment if the Bridge ends in December 2027?
Coming to your appointment prepared signals to your doctor that you understand the system and need their active help navigating it, not just a prescription that gets denied at the pharmacy.
No waiting list. No insurance needed.
Frequently Asked Questions
What is the Medicare GLP-1 Bridge?
It is a temporary CMS demonstration that runs from July 1, 2026, through December 31, 2027. Eligible Medicare Part D enrollees pay $50 for a one month supply of Foundayo, Wegovy (injection or tablet), or Zepbound KwikPen when the drug is used for weight management. It operates outside your regular Part D plan.
Why are people with type 2 diabetes excluded from the Bridge?
CMS excludes people with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease because GLP-1s for those conditions are already approved Part D uses. Your regular drug plan is supposed to cover them, but you pay your plan's cost sharing, which depends on the formulary and tier and may be higher than $50 a month.
Can I use a manufacturer coupon for GLP-1s if I'm on Medicare?
Generally no. Manufacturer savings cards are for commercially insured patients and exclude Medicare and other government insurance. Patient assistance programs from Novo Nordisk and Eli Lilly are a separate pathway and may help low income Medicare beneficiaries who meet their criteria.
I'm already on Wegovy through my Part D plan. Can I switch to the $50 Bridge?
Not under current rules. Medicare says people whose Part D plan has paid for a GLP-1 aren't eligible for the Bridge, but they can keep getting the drug through their plan. Ask your plan about your cost sharing and whether the Medicare Prescription Payment Plan could spread your costs out.
Does the Bridge cover Ozempic, Mounjaro, or compounded semaglutide?
No. The Bridge covers only Foundayo, Wegovy (injection or tablet), and the Zepbound KwikPen. Ozempic, Mounjaro, compounded GLP-1s, and single dose Zepbound vials and pens are not covered. Ozempic and Mounjaro may still be covered by your Part D plan for type 2 diabetes.
How does the Medicare Part D out of pocket cap affect GLP-1 costs?
The old donut hole was eliminated in 2025, and Part D now has a yearly out of pocket cap of $2,000 in 2025 and $2,100 in 2026. GLP-1 costs paid through your Part D plan count toward that cap, but the $50 Bridge copay does not. The Medicare Prescription Payment Plan can spread Part D costs into monthly payments.
The Bottom Line: Coverage Gaps Are Real, But So Are Your Options
The Medicare GLP-1 Bridge is a genuine change. For the first time, many Medicare enrollees with obesity can get Foundayo, Wegovy, or Zepbound KwikPen for a flat $50 a month without needing a separate qualifying diagnosis.
But the program draws hard lines. People with type 2 diabetes, sleep apnea, or fatty liver disease are sent back to their regular Part D coverage, people already on a Part D covered GLP-1 can't switch in, and the whole program is scheduled to end after 2027.
Don't Navigate This Alone
The right path depends on your plan, your starting BMI, your diagnoses, and your income. A single conversation with your doctor, your plan, or a State Health Insurance Assistance Program (SHIP) counselor can uncover options you didn't know you had.
If you're still researching your options, here's where to start:
- Read Medicare's own Bridge eligibility page at Medicare.gov to check the current criteria.
- Review the Best Providers page to compare telehealth services that can prescribe and handle prior authorizations.
- Learn more about specific medications like Wegovy, Ozempic, and Mounjaro to understand which might fit your health profile.
And as always, before making any changes to your medications or treatment plan, consult your physician. Your doctor knows your full medical picture and can help you choose the coverage route that works best for you.